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Abstract
Background and objective: The 12-item Multiple Sclerosis Walking Scale (MSWS-12) is a patientreported outcome instrument that quantifies the progressive loss of walking ability from the patient
perspective. However, previous psychometric analyses indicated floor and ceiling effects across the
multiple sclerosis severity spectrum. This study aimed to address floor effects by creating a gait module
that can be used in conjunction with the MSWS-12 for better measurement of treatment benefit in
the higher functioning multiple sclerosis population.
Methods: We used a step-wise mixed methods study design, with relapsing–remitting multiple sclerosis
patients (wave 1, n=88; wave 2, n=30), combining qualitative (concept elicitation and cognitive debriefing interviews) and quantitative (Rasch Measurement Theory) data collection and analytical techniques
and consultation interviews with three neurologists specializing in multiple sclerosis.
Results: Thirty-seven walking ability concepts were identified, and a five-domain conceptual framework was created. Draft items were generated and refined with patient and neurologist input. Draft
items covered gait-related concepts such as dragging, shuffling, limping, tripping and falling. Rasch
measurement theory psychometric analysis indicated administering MSWS-12 plus gait items improved
measurement precision in targeted populations with better walking ability.
Conclusion: Study findings indicate that new gait items could improve sensitivity to detect clinical
change in walking ability for higher functioning multiple sclerosis patients.
Keywords: Walking ability, multiple sclerosis, MSWS-12, patient-reported outcomes, Rasch measurement theory
Date received: 31 January 2018; Revised received 30 April 2018; accepted: 17 May 2018

Introduction
Loss of walking ability is a hallmark of functional
decline in multiple sclerosis (MS),1 and is important
to monitor as it signals changes in disease severity
and progression.2 Recent developments regarding
diagnosis and treatment also warrant consideration.
MS patients are being diagnosed earlier in the
disease course3 and are maintaining function,
particularly walking ability, for longer periods of
time.4 Furthermore, emerging therapies, particularly

remyelinating therapies, can potentially improve
walking ability.5,6
In clinical trials, walking ability is often assessed
using performance outcome measures, including
the timed 25-foot walk and the six-minute walk
test.7 However, these measures have a limited connection to functional ability and the impact on
patients’ day-to-day lives. Because including
patient-reported outcome (PRO) measures in clinical
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trials is increasingly important from a development
and regulatory perspective,8 we need robust, well
targeted PRO measures of walking ability to capture
this information, particularly in patients with more
mild walking dysfunction.
The Multiple Sclerosis Walking Scale 12-item
(MSWS-12) is a PRO measure that is widely used
to address this need.7 MSWS-12 comprises 12 items
describing the impact of MS on walking, identified
from a larger pool of 141 items derived from
patients, clinicians and literature about the ‘health
impact of MS.9 MSWS-12 was psychometrically
validated using classic test theory methods.
However, more recent research using modern test
theory methods (Rasch Measurement Theory;
RMT) detected disordering in the instrument’s
response categories and poor targeting at the floor
of the scale,10 suggesting that MSWS-12 may be less
sensitive to change in patients with more subtle deficits in walking ability. In addition, like many legacy
PRO measures developed prior to regulatory guidance emphasizing conceptual clarity,11 MSWS-12
was not developed based on a well-defined, comprehensive conceptual framework.9
The objective of this research was to address the
floor effect of the MSWS-12 and its sensitivity to

change in walking ability in early stage relapsing–
remitting multiple sclerosis (RRMS) patients.
In alignment with regulatory and professional guidance for addressing measurement issues in existing
PRO measures,12,13 we conducted patient-centered
research to develop new items that measure symptoms and functional impact of walking limitations in
early MS and potentially across the spectrum of
MS severities.
Materials and methods
Study design overview
We performed patient-centered research to expand
and refine our understanding of the concept of interest – walking ability in less disabled people with
MS – to create a conceptual framework of treatment
benefit and pilot test potential new items. The
research comprised two waves of patient interviews
and consultation with three clinical neurologists in
MS at each stage. Interviews collected both qualitative (discussion) and quantitative (PRO response)
data, which allowed us to conduct a mixed methods
analysis (see Figure 1). In psychometric research,
‘mixed methods’ refers to the synthesis of qualitative and quantitative methods to identify, define
and operationalize PRO instruments as measures

Interviews with n=88 RRMS paents
Walking concept elicitaon
Complete & debrief original MSWS-12

Wave 1
Mixed methods analysis
Qualitave coding, MS specialist feedback
Quantave RMT Analysis
Dra item development

37 walking concepts
5-domain conceptual framework
Dra 9-item GAIT measure

Interviews with n=30 RRMS paents
Test (debrief) new items
Complete original MSWS-12 + new items to
enable small scale analysis

Wave 2
Mixed methods analysis
Qualitave coding, MS specialist feedback
Quantave RMT Analysis
2 rounds item reﬁnement

10-item GAIT measure

Figure 1. This Figure outlines the methods, analyses and main outocmes for each of the twowaves of this research.
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of a given concept of interest in a specific context
of use.14
Study population and recruitment process
Institutional review board approval was obtained,
and participants provided written informed consent.
Early RRMS patients were recruited through the
study sponsor’s patient services department and
through a social media site for MS patients.
Eligible patients were diagnose d with RRMS
within the last 2 years and had a patient determined
disease steps (PDSS)15 score of 0–1 (no to mild disability). This PDDS range coincides with the
Expanded Disability Status Scale (EDSS) 0–2
levels,16 in which recent research indicated limitations in the MSWS-12’s measurement range and precision (i.e. floor effects).
Patient interviews
Two waves of patient interviews were conducted.
Wave 1 concept elicitation interviews followed a
semistructured interview guide that fostered discussion around symptoms and impacts experienced in
early MS. Patients also completed and discussed the
MSWS-12. Data from wave 1 interviews allowed us
to identify aspects of walking ability relevant to this
sample and to create a conceptual framework
to organize meaningful aspects of walking ability
that can be used to evaluate treatment benefit in
the context of clinical research.8 From these data,
we generated new items to address the floor effect
in the MSWS-12.
Wave 2 interviews were cognitive debriefing interviews to establish relevance, clarity and ease of completion of the draft items that were generated after
wave 1. Patients followed a ‘think aloud’ process,
completing the items while explaining their thought
process and noting any problems or ambiguities in
these items.17 Patients also completed the MSWS-12
and new items to provide quantitative data for
RMT analysis.
All interviews were conducted over the telephone;
the MSWS-12 and new draft items were displayed
on patients’ computer screens, and item responses
were captured by means of an online platform.
Interviews were audio-recorded and transcribed.
Three neurologists specializing in MS (SC, MDG,
KKR) were consulted after each of the waves
to confirm the clinical relevance of the concepts
elicited and to provide feedback on the emerging
conceptual framework and items.

www.sagepub.com/msjetc

Data analysis
Wave 1 qualitative analysis: concept elicitation.
Transcripts were analyzed thematically18 through
detailed line-by-line coding,19 using ATLAS.ti
software.20 Coding was targeted to capture walking
ability concepts. Codes and quotations were inductively categorized into overarching domains. Each
code was compared with the rest of the data to
create analytical domains and subdomains.
Saturation, or the point in the data collection process
when no new concept-relevant information emerges
from additional qualitative data,21 was assessed by
ordering interviews chronologically, grouping them
into quantiles and comparing concepts emerging by
each sequential quantile.

Development of conceptual framework, concept
mapping to MSWS-12 and item generation.
Patient-generated walking ability concepts were
inductively categorized into domains to create a conceptual framework of walking ability in MS.
Concepts and domains were mapped against the
MSWS-12 to identify concepts important to patients
that were not in the existing instrument.
Item generation followed item construction
principles,11,22–24 aiming to have an adequate range
of items to cover the selected domain of walking
ability. Item construction used as many of the
patients’ own words as possible.

Wave 2 qualitative analysis: cognitive debriefing.
This analysis aimed to identify wording ambiguities
and assess relevance and acceptability in relation to
each new item, response scale and set of instructions.
Additional items suggested by wave 2 participants
that could further expand the measurement of walking
disability in early RRMS were also explored.17

Quantitative data analysis. Small-scale RMT analysis was performed using MSWS-12 data from wave 1
and MSWS-12 plus complimentary items data from
wave 2 using RUMM 2030.25 RMT analysis was
performed on the original PRO instrument scoring
and on the revised scale structure proposed following
preliminary analysis.26 RMT analysis compares
observed data against the stringent criteria of the
Rasch model, aiming to assess the sample-to-scale
targeting, item performance and person fit.27,28

3
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Results
Study sample
A total of 118 patients with RRMS participated in
this research study (n=88 wave 1; n=30 wave 2).
Difficulties with walking were reported by 78%
(n=69) of wave 1 patients at screening; all patients
in wave 2 reported walking difficulty. Most patients
were women (wave 1, 74%; wave 2, 80%), and the
sample in both waves was evenly divided between
PDDS 0 (50%) and 1 (50%) (see Table 1).
Wave 1: concept elicitation. Patients reported 37
unique concepts related to walking ability. Table 2
lists these concepts, while Table 3 provides exemplar quotes illustrating walking concepts. Patients
described decreasing walking capacity in speed,

distance or duration that varied based on the walking
context, such as stairs or unfamilar terrain. They also
discussed adapations they employed to deal with
walking problems such as leaning on furniture
or walls and concentrating when walking. Patients
further described their walking ability in terms of
gait problems, including shuffling, stumbling, tripping and falling. These higher functioning patients
reported that while the walking issues they experienced on a day-to-day basis were relatively minor,
they affected their quality of life. Most patients
described proactively limiting activities such as
shopping, walking with friends, hiking on rough
terrain, or walking long distances based on concerns
about their walking ability. Patients explained that
their walking ability was usually severely impacted
during flares; on a day-to-day basis, walking could

Table 1. Sample characteristics.

Patient demographic and
clinical characteristics
PDSS score (N, %)
0 – normal
1 – mild disability
Age in years
Mean (SD)
Gender (N, %)
Male
Female
Race/ethnicity (N, %)
White
Asian
Black/African-American
Hispanic/Latino
Mixed race or ‘other’
Education (N, %)
High school
Some college/AA degree
Trade certification
Bachelor’s degree
Postgraduate degree
Employment statusa (N, %)
Full time
Part time
Not employed
Student
Homemaker

Wave 1 concept
elicitation
sample (n¼88)
44 (50%)
44 (50%)

Wave 1 RMT
analysis
sample (n¼29)

Wave 2
debriefing
and RMT
sample (n¼30)

12 (41.4%)
17 (58.6%)

15 (50.0%)
15 (50.0%)

40.0 (8.72)

38.34 (8.62)

38.9 (7.89)

23 (26.1%)
65 (73.9%)

8 (27.6%)
21 (72.4%)

6 (20.0%)
24 (80.0%)

76
1
5
5
1

24
0
3
2
0

24
0
4
1
1

(86.4%)
(1.1%)
(5.7%)
(5.7%)
(1.1%)

(82.8%)
(0.0%)
(10.3%)
(6.9%)
(0.0%)

(80.0%)
(0.0%)
(13.3%)
(3.3%)
(3.3%)

11 (12.5%)

1 (3.4%)

0 (0.0%)

28 (31.8%)
32 (36.4%)
17 (19.3%)

13 (44.8%)
13 (44.8%)
2 (6.9%)

13 (43.3%)
8 (26.7%)
9 (30.0%)

57
14
10
2
5

19
6
2
1
2

20
3
7
1
1

(64.8%)
(15.9%)
(11.4%)
(2.2%)
(5.7%)

(65.5%)
(20.7%)
(6.9%)
(3.4%)
(6.9%)

(66.6%)
(10.0%)
(23.3%)
(3.3%)
(3.3%)

a

Counts not mutually exclusive; some patients reported more than one employment status.
RMT: Rasch measurement theory.
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Table 2. Conceptual framework of walking ability in early RRMS, mapping to MSWS-12.
Adaptation

Balance and
coordination

Walking ability in early RRMS
 Walking/
 Walking
standing
balance
support
 Standing
 Need to
balance
concentrate  Coordination

Capacity

Context

Gait

 Running ability
 Walking ability
 Walking distance
 Walking speed
 Bending forward
 Crouching
 Raising leg/foot
 Rising from flat
surface or sitting
 Standing
 Stepping up
 Unable to walk
(immobile)
 Walking duration

 Uneven surface
 Unfamiliar terrain
 Escalators
 Stairs

 Gait problemsa
 Bumping into things
 Drop foot
 Falling
 Feeling clumsy
 Foot drag
 Knee gives out
 Leaning while walking
 Leg drag
 Leg gives out
 Limp
 Locking extremities
 Shuffling
 Stumbling
 Toe/foot position
 Toe drag
 Tripping

 Indicates concept covered by MSWS-12.
a
Concept elicited similar to MSWS-12 item 11 (affected how smoothly you walk).
RRMS: relapsing–remitting multiple sclerosis; MSWS-12: Multiple Sclerosis Walking Scale 12-item.

Table 3. Examples of patient descriptions of walking concepts.
Concept codes

Example quotes

Locking extremitiesStairs
Leg gives out

It was more my leg would just kind of lock up. It was
particularly scary if I was going down the stairs.
I just got out of bed that morning, just as normal, and my
right leg just gave out. There was no pressure. It literally
just came from under me.
Even just regular standing I would rather stand against a
wall, because my balance still isn’t great.
But if I’m in a new place or I’m walking – for example,
across a parking lot, and I know a curb’s coming up, and
I’m looking. Any kind of terrain I don’t know, I have to
really – I concentrate and make sure I don’t stumble over
anything, because I’m always concentrating on making
sure I don’t fall.
Walking. I have a trail behind my house that I walk every
day. And now I’m not as able to do the whole – I can’t do
the whole trail.

Standing balance
Unfamiliar terrain
Uneven surface
Need to concentrate

Walking distance

be affected by weakness, neuromuscular symptoms
(e.g. tremor, spasm, numbness), fatigue and fatigability, proprioceptive and vestibular problems
and pain.

www.sagepub.com/msjetc

Saturation analysis found that 33 of 37 of the initially identified walking-related concepts arose within
the first 40 interviews. The four concepts elicited in
the remaining 48 interviews were similar to concepts
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Table 4. Saturation of walking concepts (n¼37).
Interview

1–10

11–20

21–30

31–40

41–50

51–60

61–70

71–80

81–88

Number of
concepts

22

7

1

3

0

0

2

1

1

derived from the first 40 interviews, indicating that
interviews produced a comprehensive picture of
walking-related concepts in higher functioning
patients with RRMS (see Table 4).
Conceptual framework, concept mapping to MSWS12 and item generation. To understand better the
impact on walking ability in MS and to inform a
conceptually clear measurement strategy for generating new items, concepts related to walking ability
were inductively categorized into five conceptual
domains (see Table 2):
• Adaptation: methods patients employ to adapt to
walking limitations;
• Balance and coordination: problems remaining
upright and steady;
• Capacity: limitations on the ability to walk, run,
or stand;
• Context: limitations on walking in certain
environments;
• Gait: problems reported with the manner
of walking.
Elicited concepts were then mapped to the MSWS12 to determine its conceptual coverage and identify
gaps. Of the 37 concepts elicited from higher functioning RRMS patients, 28 were not assessed by
items of the MSWS-12 (see Table 2).
At this stage, item development was informed by
consultation with clinicians specializing in MS
and reference to the conceptual framework. First,
clinicians reviewed the conceptual framework and
walking concepts elicited from patients to determine
their suitability for extending the measurement
range of the MSWS-12 for patients with less
severe disability. Of the 28 concepts not included
in the MSWS-12, 13 were endorsed by two of the
three clinical experts as additional items to extend
the range of the MSWS-12: bending, crouching, raising leg/foot, drop foot, escalators, foot drag, leaning
while walking, leg gives out, rising from sitting/low
position, shuffling, tripping, walking duration and
concentrating while walking.

6

Clinician recommendations were then examined
considering gaps in MSWS-12 coverage and with
reference to the walking conceptual framework.
MSWS-12 does not offer comprehensive coverage
in any of the five domains of walking except adaptation. While all five domains within the walking
conceptual framework could be developed into distinct MS walking scales, developing gait items
appeared to provide the best opportunity to address
a gap in MSWS-12 coverage. This could also
enhance measurement of treatment benefit in less
disabled patients. MSWS-12 offers only one gait
item, ‘affected how smoothly you walk’, most similar to descriptions of the ‘gait problems’ concept
elicited in interviews. Given that two of three clinicians endorsed six gait concepts (drop foot, foot
drag, leaning while walking, leg gives out, shuffling
and tripping) as relevant for higher functioning
patients, and an additional five concepts (drop foot,
leg drag, foot drag, toe drag, limp) as more relevant
for lower functioning patients, patient-elicited concepts in this domain offered the potential to develop
items that could assess walking ability across the
broad range of MS severity.
Gait items were developed in alignment with best
practices for item development. Gait concepts were
assessed in light of clinician feedback, patient comments, redundancies with existing MSWS-12 items,
potential item formulation problems (e.g. ‘doublebarreled’ items assessing more than one domain or
describing more than one task) and potential to
extend the measurement of the concept of interest.
Nine draft gait items were developed, with response
options and instructions formatted to complement
the MSWS-12 (see items 1–9, Table 5).
Wave 2: cognitive debriefing. Debriefing the nine
draft gait items with 30 early RRMS patients demonstrated that overall these items were relevant, well
understood and acceptable to patients. Some concerns were identified with items 02, 03 and 05.
Item 05 (be clumsy) presented the most interpretation difficulty; half the patient sample reported
that they considered upper limb clumsiness when
responding to this item. Two patients stated that
items 02 (legs give out) and 03 (legs lock up)

www.sagepub.com/msjetc

Strzok et al.

Table 5. MSWS-12 and gait items.
MSWS-12 items
01
Limited your ability to walk?
02
Limited your ability to run?
03
Limited your ability to climb up and down stairs?
04
Made it more difficult to stand while doing things?
05
Limited your balance while standing or walking?
06
Limited how far you are able to walk?
07
Increased the effort needed for you to walk?
08
Made it necessary to use support when walking indoors (e.g. holding
onto furniture, using a cane, etc.)?
09
Made it necessary to use support when walking outdoors (e.g. using
a cane, a walker, etc.)?
10
Slowed down your walking?
11
Affected how smoothly you walk?
12
Made you concentrate on your walking?
Gait items
01
Caused you to drag your legs or your feet?
02
Caused your knees or legs to give out, buckle or collapse?
03
Caused your legs to become stiff or lock up?
04
Caused you to bump into things?
05
Caused you to be clumsy when you walk?
06
Caused you to shuffle?
07
Caused you to walk with a limp?
08
Caused you to trip?
09
Caused you to fall?
10
Caused you to have trouble walking in a straight line?
Wording in bold revised or added after wave 2 interviews based on patient and clinician feedback.
MSWS-12: Multiple Sclerosis Walking Scale 12-item.

were the same; an additional three patients stated
they did not understand what was meant by ‘lock
up’. Some patients suggested adding clarifying
wording to item 02 (legs or knees give out) including
‘losing control’, ‘buckling’, or ‘weakness’. To clarify item 03 (legs lock up), two patients suggested
specifying which part of the leg locks up. Patients
were also asked whether any important questions
were missing from the gait measure; one patient
suggested adding an item on walking to the side
instead of in a straight line.
Final gait items. Clinicians reviewed patient feedback on the draft gait items and suggested item revisions and potential additions. Based on patient and
clinician feedback, three gait items were revised for
better comprehension (item 02, legs or knees give
out; item 03, legs lock up; item 05, be clumsy) and
one new item (item 10, trouble walking in a straight
line) was added (see Table 5).

www.sagepub.com/msjetc

Quantitative data analysis. Analysis of MSWS-12
data from wave 1 indicated that sample-to-scale targeting of the scale was suboptimal. Many items
appear not relevant for the sample as there are
no measurements on the right-hand side of the continuum (ceiling: worse walking ability); whereas
measurement for some people on the left (floor:
better walking ability) is not matched by any items
of equivalent difficulty in relation to walking
(see Figure 2).
Combining MSWS-12 and gait items resulted in
better targeting to the early MS sample (Figure 2
(b)). The person-item threshold plot of the combined
scales indicates that all but three of the new gait items
(legs lock, shuffle and limp) sit on the lower end of
the continuum (better walking ability) and therefore
improve MSWS-12 targeting on the floor of the scale.
Adding new gait items increased relative coverage of
the range of walking ability measured by the scale in
this sample to 74% from 70%. Increased coverage
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Figure 2. Sample-to-scale targeting. This figure provides a direct comparison of walking ability within the sample and
within the scale items. The upper histograms (pink blocks) represent the sample distribution and the lower histograms
(blue blocks) the scale item threshold distribution plotted on the same interval metric continuum of walking ability.
(a) Sample-to-scale targeting of the original MSWS-12 items and (b) the improvements to the match between sample and
scale targeting introduced by merging the original MSWS-12 with the gait module items. Sample measurements falling
off the 0–100 range of the scale indicate patients for whom the scale remains too easy.

improves a scale’s precision and sensitivity associated
with measurement, as evidenced by the sum and average standard error scores associated with person estimates that decreased from 18.29 to 13.657 and 0.61 to
0.46 respectively.
No item misfit was identified; all items displayed fit
residuals within recommended ranges and none of the
items displayed significant chi-square correlations.
However, the five-level response scale only worked
as intended for 11 of 21 items, suggesting patients
may have had difficulty discriminating among the
five response options. In addition, 13 pairs of items
displayed residual correlations above the recommended level (>0.3), suggesting possible dependency
between items, which can impact true reliability.
Despite this, the reliability of the combined item
sets with and without extremes was good (PSI 0.90/
0.90) and person misfit was low (n=3; 10%). This
suggests good measurement precision in a good quality dataset. Figure 2 illustrates the improved sampleto-scale targeting of MSWS-12 plus gait items.
Discussion and conclusions
The patient’s perspective is a central part of clinical
research as evidenced by the recently published 21st
Century Cures Act 2016, which emphasizes patientcentered outcomes.29 In addition, well defined and
reliable PRO instruments have been considered
essential by the US Food and Drug Administration

8

for over a decade.11,12 Walking is a central concept
of interest for MS clinical trials. While its objective
measurement is vital, the patient’s real-world experience needs to be integrated to provide meaning and
context to standardized walking assessments.
A notable example is the AMPYRA (dalfampridine)
label, in which the MSWS-12 was used to provide
meaning to the results of the timed 25-foot walk.30
In this study, we have begun to address the issues
around floor effects previously identified in the
MSWS-12, and thus improve the potential to
detect therapeutic effects in clinical trials, research
and ultimately, practice. Our study, which bridges
the 12 original MSWS items with 10 new gait
items, demonstrates one way to improve targeting
and sensitivity to change across a wider range of
MS severity. This multi-phase, mixed methods
study (together with companion studies presented
elsewhere)31,32 addresses the knowledge and measurement gaps around the symptom experience of
higher functioning MS patients, presenting a clearer
picture of the entire experience of patients affected
by MS from early diagnosis onwards.
Our patient-centered research with 88 patients
resulted in a rich pool of walking concepts relevant
in early RRMS, from which a five-domain conceptual
framework of walking ability in MS was generated.
Because it had the best potential to address concepts
not included in the MSWS-12, we chose the gait

www.sagepub.com/msjetc
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domain for item development. Ten candidate items
were produced to enhance the measurement of walking ability in MS, particularly in higher functioning
patients with better walking ability. Clinical neurologists helped ensure that item development focused on
the most clinically relevant items to measure walking
ability within this domain. Wave 2 interviews with 30
additional patients confirmed the relevance and
understanding of the new items and provided evidence used to revise and refine the items.
Preliminary psychometric analysis of the MSWS-12
plus new items suggests improved targeting in this
higher functioning RRMS sample, with reduced
floor effects and greater precision in the ability to
discriminate different levels of walking ability.
Importantly, the item map of the combined scale indicates that all but three of the new gait items (legs lock
up, shuffle and limp) sit on the lower end of the continuum (better walking ability), results that align with
the clinical assessment of the difficulty or severity of
these items. Thus when administered together with
MSWS-12, gait items improve the MSWS-12’s
scale targeting on the lower end of the scale, and
importantly, results indicate our proposed gait
module can be used as a standalone PRO instrument.
Findings should be interpreted with consideration of
the study’s limitations. A new item (item 10, trouble
walking in a straight line) was added after wave 2
interviews and clinician discussions; no performance
data are available for this item. Recruitment methodology dictated that inclusion criteria were based on
self-report information rather than a clinically confirmed diagnosis of RRMS. In addition, while preliminary psychometric results are promising, the small
sample size and targeted mild disability population
for the RMT analysis require that these results be
interpreted with caution. Potential issues relating to
thresholds and dependency should be revisited in
larger, broader samples to decide on the best steps
forward. Additional analysis in a larger, clinically
defined sample would help confirm the validity and
generalizability of these findings as well as the new
items’ measurement properties. Finally, the MSWS12 and gait item stems (‘In the past two weeks, how
much has your MS . . .’) are simple and walking
descriptions are brief, presenting low cognitive
burden. However, given that the enhanced conceptual
coverage in higher functioning patients is achieved by
administering 10 items in addition to the MSWS-12
items, it may be worthwhile to explore the time
needed to complete the gait items in future studies.

www.sagepub.com/msjetc

Created using best practices for PRO item development, the new gait items are potentially well suited
to measure gait ability across the spectrum of MS,
while specifically addressing measurement issues in
less disabled patients. Greater sensitivity to change
in this higher functioning population will allow more
accurate measurement of walking disability progression and of reversal of disability when it occurs.
Capturing this experience of walking ability enriches
our understanding of functioning in the MS population represented now and enhances the likelihood of
understanding the potential benefits of emerging
therapies that may halt, or even reverse, early disease progression. Next steps include a full validation
study to understand the psychometric properties of
the overall item set across a broad MS population.
Following that, additional modules covering the
remaining four domains (adaptation, balance and
coordination, capacity and context) could be developed using a similar mixed methods process.
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